StreetInsider.com News Articles

PetMed Express (PETS) PT Lowered to $1.40 at Morgan Stanley

Fri, 25 Sep 2026 08:27:57 -0400

Morgan Stanley analyst Erin Wright lowered the price target on PetMed Express (NASDAQ: PETS) to $1.40 (from $2.15) while maintaining a Underweight rating.

Form 4 PETMED EXPRESS INC For: Sep 17 Filed by: Elkeles Tamar

Mon, 21 Sep 2026 08:59:00 -0400

si-local-file:///var/storage/secattach/20260921/27083534.html

Form 3 PETMED EXPRESS INC For: Sep 17 Filed by: Elkeles Tamar

Mon, 21 Sep 2026 08:55:00 -0400

si-local-file:///var/storage/secattach/20260921/27083524.html

Form 8-K PETMED EXPRESS INC For: Sep 15

Mon, 21 Sep 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260921/27083423.html

PetMeds adds Tamar Elkeles to its board as independent director

Mon, 21 Sep 2026 08:31:45 -0400

PetMed Express, Inc. (NASDAQ: PETS), the parent company of PetCareRx, announced the appointment of Tamar Elkeles, PhD, as a new independent director and Chair of the Compensation and Human Capital Committee, effective September 17, 2026.

Dr. Elkeles has more than three decades of experience as an executive, board member, and strategic advisor in the technology, enterprise software, and human capital industries. From 1992 to 2015, she served as Chief Learning & Talent Officer at Qualcomm, where she contributed to the company's growth from $100 million to more than $25 billion in revenue and its workforce expansion from 700 to 35,000 employees.

She

PetMeds adds Tamar Elkeles to its board as independent director

Mon, 21 Sep 2026 08:31:45 -0400

She

PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director

Mon, 21 Sep 2026 08:30:00 -0400

DELRAY BEACH, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Tamar Elkeles, PhD as a new independent director and Chair of the Compensation and Human Capital Committee, effective September 17, 2026.

Dr. Elkeles brings more than three decades of experience as an executive, board member, and strategic advisor across the technology, enterprise software and human capital industries. From 1992 to 2015, she served as Chief Learning & Talent Officer at Qualcomm, where she helped shape the human capital strategy that supported

PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director

Mon, 21 Sep 2026 08:30:00 -0400

Form 8-K PETMED EXPRESS INC For: Sep 17

Thu, 17 Sep 2026 09:09:00 -0400

si-local-file:///var/storage/secattach/20260917/27073702.html

PetMeds names Jeff Willard as CEO, board chair to retire

Thu, 17 Sep 2026 08:30:36 -0400

PetMed Express, Inc. (NASDAQ: PETS), the parent company of PetCareRx, announced the appointment of Jeff Willard as Chief Executive Officer and President, effective September 28, 2026. Willard will also join the company's Board of Directors on that date.

Willard succeeds Leslie C.G. Campbell, who has served as Interim Chief Executive Officer and President since August 2025. Most recently, Willard served as CEO of Stewart-MacDonald, an e-commerce provider of guitar tools and parts. He previously held roles including Chief Growth Officer and Chief Marketing Officer at Casper, President of Healthy Lifestyle Brands, and CEO of Zac Brown Collective. Earlier positions included senior

PetMeds names Jeff Willard as CEO, board chair to retire

Thu, 17 Sep 2026 08:30:36 -0400

PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition

Thu, 17 Sep 2026 08:30:00 -0400

DELRAY BEACH, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of consumer and e-commerce sector veteran, Jeff Willard, as Chief Executive Officer and President, as well as a member of the Board of Directors, effective September 28, 2026. Mr. Willard succeeds Leslie C.G. Campbell, who, in addition to serving as Chair of the Board of PetMeds, has served as Interim Chief Executive Officer and President since August 2025.

Mr. Willard brings more than 25 years of proven leadership experience at leading consumer

PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition

Thu, 17 Sep 2026 08:30:00 -0400

Mr. Willard brings more than 25 years of proven leadership experience at leading consumer

PetMeds names Andrew Parry as chief technology officer

Mon, 14 Sep 2026 16:05:42 -0400

PetMed Express, Inc. (NASDAQ: PETS), which operates under the PetMeds brand and owns PetCareRx, announced the appointment of Andrew Parry as Chief Technology Officer, effective immediately, according to a company press release.

Parry will oversee technology strategy, platform architecture, and engineering across the company's e-commerce, pharmacy, and enterprise systems.

Parry joins PetMeds from The ODP Corporation, where he served as Senior Vice President and Chief Information Officer. In that role, he led technology operations for the company's retail, business solutions, and supply-chain units and executed a multi-year initiative to implement generative AI and workflow automation. He was appointed Chief Information Officer at

PetMeds Appoints Andrew Parry as Chief Technology Officer

Mon, 14 Sep 2026 16:05:00 -0400

DELRAY BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Andrew Parry as Chief Technology Officer, effective immediately. Parry will lead the Company's technology strategy, platform architecture and engineering execution across its e-commerce, pharmacy and enterprise systems.

Parry brings more than three decades of technology leadership experience and joins PetMeds from The ODP Corporation, where he most recently served as Senior Vice President and Chief Information Officer, leading technology for the retail, business solutions and supply-chain units. In that

PetMeds Appoints Andrew Parry as Chief Technology Officer

Mon, 14 Sep 2026 16:05:00 -0400

Form 4 PETMED EXPRESS INC For: Aug 11 Filed by: Campbell Leslie C.G.

Thu, 13 Aug 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260813/26922640.html

Form 4 PETMED EXPRESS INC For: Aug 11 Filed by: Campbell Leslie C.G.

Thu, 13 Aug 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260813/26922640.html

Form 10-Q PETMED EXPRESS INC For: Jun 30

Thu, 13 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260813/26922446.html

Form 10-Q PETMED EXPRESS INC For: Jun 30

Thu, 13 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260813/26922446.html

Form SCHEDULE 13G/A PETMED EXPRESS INC Filed by: RENAISSANCE TECHNOLOGIES LLC

Thu, 13 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260813/26921659.html

Form SCHEDULE 13G/A PETMED EXPRESS INC Filed by: RENAISSANCE TECHNOLOGIES LLC

Thu, 13 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260813/26921659.html

PetMed Express (PETS) Misses Q1 EPS by 40c

Thu, 13 Aug 2026 16:22:03 -0400

PetMed Express (NASDAQ: PETS) reported Q1 EPS of ($0.28), $0.40 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $41.01 million versus the consensus estimate of $71 million.

For earnings history and earnings-related data on PetMed Express (PETS) click here.

Form 8-K PETMED EXPRESS INC For: Aug 13

Thu, 13 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26921454.html

Form 8-K PETMED EXPRESS INC For: Aug 13

Thu, 13 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26921454.html